PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ultragenyx

Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives an Extended Approval for Evkeeza by the EC for 5 Years or Older Children with Homozygous Familial Hypercholest...

December 19, 2023

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in the P-III Program for Osteogenesis Imperfecta

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in the P-III Program for Osteogenesis Imperfecta

July 7, 2023

Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A

Ultragenyx Entered into an Exclusive License Agreement with Abeona for ABO-102 (UX111) to Treat Sanfilippo Syndrome Type A

May 18, 2022

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Imperfecta

Ultragenyx Reports the First Patient Dosing of Setrusumab (UX143) in P-II/III (Orbit) Study for the Treatment of Osteogenesis Impe...

April 21, 2022

PharmaShots Interview: n-Lorem Foundation's Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide Personalized Medicines to Ultra-Rare Patients

PharmaShots Interview: n-Lorem Foundation's Dr. Stanley T. Crooke Shares Insights on its Collaboration with Ultragenyx to Provide...

June 15, 2021

PharmaShots Weekly Snapshots (April 05 - 09, 2021)

PharmaShots Weekly Snapshots (April 05 - 09, 2021)

April 9, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us